PDCD1 and melanoma: Interestingly, the same group demonstrated that GSK-3 inhibition with SMIs was as effective as anti-PD-1 and PD-L1 blocking antibodies in the suppression of tumor growth of melanoma and lymphoma cells in primary tumor and metastatic mouse models [101].